Regarding PAH drugs, the three current therapeutic targets are the endothelin pathway, the nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway, and the prostacyclin pathway [55]. This evidence concerns the gene SGCB and pulmonary arterial hypertension.